United Drug delivers solid first half results

FTSE 250-listed outsourced commercialisation services provider United Drug delivered solid results for the first half of the year underpinned by growth in its US packaging division.

FTSE 250-listed outsourced commercialisation services provider United Drug delivered solid results for the first half of the year underpinned by growth in its US packaging division.

Operating profits across the group in the six months to March 31st were up 13% and revenue was up 14% to €1.02bn, from the corresponding period in 2012.

Earnings per share were 7.0% higher on the same period of 2012. Strong cash flow performance was recorded with operating cash flow of €55.8m in the period, significantly up on the €20.4m generated in the same period of 2012.

The packaging and specialty division revenue for the period was recorded at €99m, 26% higher than the same period in 2012, with operating profit growing by 25%.

Revenue for the Sales, Marketing & Medical division of €182m was 113% higher than the same period in 2012. Much of the growth came from the recently acquired Pharmexx businesses, the group said, which had lower margins than its existing business at the time of acquisition.

Revenue for the Healthcare Supply Chain division for the period of €736m was 1.0% ahead of 2012. Operating profits increased by 2.0% over the same period in 2012.

In September, the group plans to re-brand as 'UDG Healthcare', subject to shareholder approval so as to apply brand consistency within each division. The group said that an EGM notice seeking approval for the change would be circulated to shareholders in the coming weeks.

Liam FitzGerald, Chief Executive Officer of United Drug, commented: "The first half of 2013 has seen us integrate our recent acquisitions, structure our business for future growth and deliver 13% operating profit growth."

He added: "During the period, the US became our largest profit contributing region, followed closely by the UK and the rest of Europe. We continue to work hard to provide a range and quality of professional outsourcing solutions that enable our international healthcare clients to operate more effectively."

United Drug's share price was down 0.62% to 306.20p at 10:10 on Thursday.

MF

Recommended

Broker safety – your questions answered
Investment strategy

Broker safety – your questions answered

Cris Sholto Heaton answers more of your questions about the safety of stockbroker accounts
25 Mar 2020
How demographics affects stock valuations
Investment strategy

How demographics affects stock valuations

New research suggests that stock and bond valuations are driven by the age of the population – at least in the US.
24 Feb 2020
Do you own shares in Sirius Minerals? Here’s what you need to do now
Stocks and shares

Do you own shares in Sirius Minerals? Here’s what you need to do now

Mining giant Anglo American has proposed a cash takeover of Yorkshire-based minnow Sirius Minerals. Unhappy shareholders must decide whether to accept…
20 Feb 2020
Why investors should be “cautiously bullish” for 2020
Stockmarkets

Why investors should be “cautiously bullish” for 2020

Analysts have been out in force making rosy predictions for stockmarkets in 2020, but while there is certainly a case for optimism, investors should r…
17 Jan 2020

Most Popular

Will a second wave of Covid lead to another stockmarket crash?
Stockmarkets

Will a second wave of Covid lead to another stockmarket crash?

Can we expect to see another lockdown like in March, and what will that mean for your money? John Stepek explains.
18 Sep 2020
Here’s why you really should own at least some bitcoin
Bitcoin

Here’s why you really should own at least some bitcoin

While bitcoin is having a quiet year – at least in relative terms – its potential to become the default cash system for the internet is undiminished, …
16 Sep 2020
James Ferguson: How bad data is driving fear of a second wave of Covid-19
UK Economy

James Ferguson: How bad data is driving fear of a second wave of Covid-19

Merryn and John talk to MoneyWeek regular James Ferguson about the rise in infections in coronavirus and what the data is really telling us.
17 Sep 2020